Viva Biotech HoldingsFRA:VB0 +2.59%47 Interest Coverage is 4.65 as of Dec. 2025, which is 13% below its 10-year median of 5.32. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 377 Biotechnology companies, Viva Biotech Holdings ranks worse than 84.08% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Viva Biotech Holdings's
Operating Income
for the
six
months ended in Dec. 2025 was €10.7 Mil. Viva Biotech Holdings's Interest Expense for the
six
months ended in Dec. 2025 was €-2.3 Mil.
Viva Biotech Holdings's interest coverage for the quarter that ended in Dec. 2025 was 4.65.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Viva Biotech Holdings's Interest Coverage or its related term are showing as below:
FRA:VB0'
s Interest Coverage Range Over the Past 10 Years
Min: 1.45 Med: 5.32 Max: 142.97
Current: 5.64
FRA:VB0's Interest Coverage is ranked worse than 84.08% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs FRA:VB0: 5.64
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Viva Biotech Holdings Interest Coverage Related Terms
Viva Biotech Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:VB0 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Interest Coverage of 4.65 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Viva Biotech Holdings and its competitors. This is 13% below median its historical median of 5.32. Over the past decade, Viva Biotech Holdings' Interest Coverage has ranged from 1.45 to 142.97. According to the industry distribution chart, Viva Biotech Holdings ranks #317 out of 377 companies in the Biotechnology industry, placing it in the top 84.1%.
Is Viva Biotech Holdings' Interest Coverage too high?
Viva Biotech Holdings' current Interest Coverage of 4.65 is 13% below median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 142.97. The Biotechnology industry median Interest Coverage is 106.07. Viva Biotech Holdings' value of 4.65 is 95.6% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #317 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #317 out of 377 companies for Interest Coverage. This places Viva Biotech Holdings in the lower half of its industry. The industry median Interest Coverage is 106.07. Viva Biotech Holdings' value of 4.65 is 95.6% below this benchmark. Historically, Viva Biotech Holdings' own Interest Coverage has ranged from 1.45 to 142.97 over the past decade. While the company's 10-year median is 5.32 vs. the industry median of 106.07, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Interest Coverage of 4.65 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Interest Coverage is 4.65, which is 13% below median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 48.8% above its estimated fair value. The current Interest Coverage is 4.65, which is 13% below median its 10-year median of 5.32 and 95.6% below the Biotechnology industry median of 106.07. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Interest Coverage is 4.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 48.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Interest Coverage: 4.65 (13% below median its 10-year median of 5.32)
GF Value™: €0.08 vs. price of €0.12 (48.8% above fair value)
Industry Position: 95.6% below the Biotechnology median (#317 of 377)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score
Get the complete analysis for FRA:VB0
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
